FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | 本月 ...

Core Viewpoint - Meis Health (02415) announced a mid-term dividend of HKD 0.011 per share for the six months ending June 30, 2025, to be distributed on October 30, 2025 [1] Company Summary - The company will distribute the mid-term dividend on October 30, 2025 [1] - The dividend pertains to the financial period ending June 30, 2025 [1]

Group 1 - The company, Meis Health (02415), announced a mid-term dividend of HKD 0.011 per share for the six months ending June 30, 2025, to be distributed on October 30, 2025 [1]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事為張發寶博士、李欣梅博士、王帥先生及程亮先生；非執行董事為王欣女士及閆盛楓先生；以 及獨立非執行董事為劉濤女士、余明陽先生及劉耀坤先生。 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 梅斯健康控股有限公司 | | 股份代號 | 02415 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年9月1日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 股息不涉及代扣所得稅 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 ...

Core Insights - The company, Meis Health (02415.HK), reported total revenue of RMB 125.2 million for the six months ending June 30, 2025, representing a year-on-year growth of 13.2% [1] - Gross profit reached RMB 77.5 million, with a year-on-year increase of 14.1% [1] - Net profit surged to RMB 13.2 million, reflecting an extraordinary year-on-year growth of 5,238.3% [1] Revenue Drivers - The growth in performance is primarily attributed to the industry's recovery, which has driven an increase in demand for multi-channel precision marketing [1] - Companies are accelerating their transition to evidence-driven marketing models, contributing to the revenue growth [1] Operational Efficiency - The increase in gross and net profits is supported by the establishment of an AI-driven intelligent operation system, which has enhanced efficiency and optimized sales strategies [1] - Notably, revenue from AI-related businesses reached RMB 5.6 million during the reporting period, marking it as a significant source of new growth for the company [1]

Core Viewpoint - Meiz Health (02415) reported a significant increase in both revenue and net profit for the first half of 2025, driven by the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year growth of 13.2% [1] - Net profit amounted to 13.239 million RMB, showing a remarkable year-on-year increase of 5238.3% [1] - Basic earnings per share were 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Industry Trends - The growth in total revenue is attributed to the recovery in the pharmaceutical sector [1] - There is an increasing demand for precision omnichannel marketing solutions, driven by the transformation of domestic pharmaceutical companies [1]

Core Viewpoint - Meiz Health (02415) reported a mid-year performance for 2025, showing significant growth in both revenue and net profit, driven by the recovery in the pharmaceutical industry and the shift towards evidence-driven marketing models in domestic pharmaceutical companies [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year increase of 13.2% [1] - Net profit amounted to 13.239 million RMB, reflecting a remarkable year-on-year growth of 5238.3% [1] - Basic earnings per share were 2.45 cents, with an interim dividend proposed at 1.1 Hong Kong cents per share [1] Industry Trends - The increase in total revenue is primarily attributed to the recovery in the pharmaceutical sector [1] - There is a growing demand for precision omnichannel marketing solutions, driven by the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1]

EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事為張發寶博士、李欣梅博士、王帥先生及程亮先生；非執行董事為王欣女士及閆盛楓先生；以 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 梅斯健康控股有限公司 | | 股份代號 | 02415 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月29日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.011 HKD | | 股東批准日期 | 不適用 ...

[Interim Results Announcement Summary](index=1&type=section&id=Interim%20Results%20Announcement%20Summary) [Performance Overview](index=1&type=section&id=Performance%20Overview) MedSci Healthcare reported a 13.2% year-on-year revenue growth and a 5,238.3% surge in profit for the six months ended June 30, 2025, with an interim dividend of 1.1 HK cents per share declared Key Financial Data for H1 2025 | Metric | 2025 (RMB thousands) | 2024 (RMB thousands) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 125,246 | 110,665 | 13.2 | | Cost of Sales | (47,767) | (42,729) | 11.8 | | Gross Profit | 77,479 | 67,936 | 14.1 | | Profit for the Period | 13,239 | 248 | 5,238.3 | | Profit Attributable to Owners of the Parent | 13,239 | 248 | 5,238.3 | - The Board declared an interim dividend of **1.1 HK cents** per ordinary share, totaling approximately **HKD 6,679,000**[43](index=43&type=chunk) [Revenue by Solution Category](index=2&type=section&id=Revenue%20by%20Solution%20Category) During the reporting period, revenue from precise omnichannel marketing and real-world clinical research solutions grew significantly, data and AI solutions emerged as a new growth driver, while physician platform solutions saw a decline Revenue by Solution Category (RMB thousands) | Solution Category | 2025 (RMB thousands) | 2025 (%) | 2024 (RMB thousands) | 2024 (%) | YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | Precise Omnichannel Marketing Solutions | 56,140 | 44.8 | 41,865 | 37.8 | 34.1 | | Physician Platform Solutions | 46,828 | 37.4 | 55,246 | 49.9 | (15.0) | | Real-World Clinical Research Solutions | 16,631 | 13.3 | 13,554 | 12.3 | 22.7 | | Data and AI Solutions | 5,647 | 4.5 | N/A | N/A | N/A | | Total | 125,246 | 100.0 | 110,665 | 100.0 | 13.2 | [Business Review and Outlook](index=3&type=section&id=Business%20Review%20and%20Outlook) [Industry Trends and Group Strategy](index=3&type=section&id=Industry%20Trends%20and%20Group%20Strategy) China's pharmaceutical industry reforms drive innovation and digitalization; the Group aligns by leveraging medical content and academic networks to advance AI agent applications, launching iMED_AI, NovaX, ElavaX, and establishing a Digital Intelligence Empowerment Center (DIEC) - China's pharmaceutical industry policies encourage **innovation, digital transformation, and normalized anti-corruption**, accelerating the industry's shift towards compliance, innovation, academic focus, and digitalization[5](index=5&type=chunk) - The Group launched three AI agent products: **iMED_AI** (digital interaction), **NovaX** (research inspiration and innovative design), and **ElavaX** (intelligent evaluation and optimization), completing internal testing for the **Digital Intelligence Empowerment Center (DIEC)**, with a planned launch in the second half of the year[5](index=5&type=chunk) [Operational Highlights](index=3&type=section&id=Operational%20Highlights) As of June 30, 2025, the Group's registered members exceeded **5.6 million**, with **3.33 million** certified doctors, serving over **2,000** medical institutions and **613** pharmaceutical companies, achieving **100%** coverage of global Top 20 pharmaceutical enterprises, while increasing AI R&D investment and advancing internationalization - As of June 30, 2025, the Group's cumulative registered members exceeded **5.6 million**, with **3.33 million** certified doctors[6](index=6&type=chunk) - Solutions have been provided to **12** top domestic research hospitals, with a service network covering over **2,000** medical institutions and serving **613** pharmaceutical and medical device companies, achieving **100%** coverage of global Top 20 pharmaceutical and medical device enterprises[6](index=6&type=chunk) - The Group continues to increase **AI technology R&D investment**, expanding deep applications of AI in pharmaceutical scenarios, significantly improving service efficiency and operational precision, and steadily advancing its internationalization strategy[7](index=7&type=chunk) [Overall Financial Performance](index=4&type=section&id=Overall%20Financial%20Performance) During the reporting period, the Group's total revenue increased by **13.2%** year-on-year to **RMB 125.2 million**, gross profit grew by **14.1%** to **RMB 77.5 million**, and net profit surged by **5,238.3%** to **RMB 13.2 million**, driven by industry recovery, rising precise marketing demand, and AI-driven operational efficiency, with AI-related business revenue reaching **RMB 5.6 million** Overall Financial Performance for H1 2025 | Metric | 2025 H1 (RMB millions) | YoY Growth (%) | | :--- | :--- | :--- | | Total Revenue | 125.2 | 13.2 | | Gross Profit | 77.5 | 14.1 | | Net Profit | 13.2 | 5,238.3 | | AI-Related Business Revenue | 5.6 | N/A | - Performance growth primarily benefited from industry recovery driving increased demand for multi-channel precise marketing and accelerated corporate transition to evidence-driven marketing models; gross profit and net profit growth resulted from efficiency improvements and sales strategy optimization driven by **AI-powered intelligent operational systems**[8](index=8&type=chunk) [Future Outlook](index=5&type=section&id=Outlook) The Group will continue to position itself as a 'reconstructor of the medical digitalization value chain,' leveraging its AI engine to build core solutions and a high-moat, full-value-chain service system, strengthening its leading edge through a 'resource accumulation – value transformation – business discovery' growth flywheel effect - The Group will position itself as a **'reconstructor of the medical digitalization value chain,'** leveraging its **AI engine** to build three core solutions: physician platform, precise omnichannel marketing, and real-world research[9](index=9&type=chunk) - Continuously strengthening its leading edge in the medical industry internet through a **'resource accumulation – value transformation – business discovery' growth flywheel effect**[9](index=9&type=chunk) [Dual-Driven and Globalization](index=9&type=section&id=Outlook%201%3A%20Dual-Driven%20Ecosystem%20Empowerment%2C%20Building%20a%20Globalized%20Medical%20Industry%20New%20Ecosystem) MedSci Healthcare will adhere to a 'digitalization + healthcare' dual-driven model, strengthening international development, upgrading from single-agent to multi-agent collaboration; it has established a Southeast Asia headquarters in Singapore, focusing on the Vietnamese market, and will enhance international empowerment for innovative pharmaceutical companies, assisting Chinese pharmaceutical enterprises in global expansion - Adhering to a **'digitalization + healthcare' dual-driven model**, strengthening international development, and upgrading from single-agent solutions to a **'multi-agent collaboration' model**[20](index=20&type=chunk) - In **2025**, a Southeast Asia headquarters was established in **Singapore**, with a focus on the **Vietnamese market**, and will enhance international empowerment for innovative pharmaceutical companies, providing full-chain services[20](index=20&type=chunk) [Comprehensive AI Empowerment](index=9&type=section&id=Outlook%202%3A%20Comprehensive%20AI%20Empowerment%2C%20Driving%20Research%20and%20Medical%20AI%20Upgrade) 2025 marks MedSci Healthcare's 'Year of AI Application,' with comprehensive AI technology penetration, completing the switch of its research digitalization platform to the DeepSeek model and achieving scalable revenue from some AI services; multiple AI agents have been launched, with a future transition to a 'multi-agent solution collaboration' model, exploring AI's auxiliary applications in clinical diagnosis and treatment - **2025** is the **'Year of AI Application,'** accelerating AI technology penetration, completing the switch of the research digitalization platform to the **DeepSeek model**, and achieving scalable revenue from some AI services[21](index=21&type=chunk) - Launched multiple AI agents, including **'MedSci Xiaozhi,' iMED_AI, NovaX, and ElavaX**, with a future transition to a **'multi-agent solution collaboration' model**, exploring AI's auxiliary applications in clinical diagnosis and treatment[21](index=21&type=chunk) [Precise Omnichannel Marketing Supporting Innovative Drugs](index=10&type=section&id=Outlook%203%3A%20Focusing%20on%20Precise%20Omnichannel%20Marketing%2C%20Promoting%20High-Quality%20Development%20of%20Innovative%20Drugs) The Group seized the industry recovery opportunity, achieving significant growth in precise omnichannel marketing with market recognition for its professional capabilities; national policies support innovative drug development and real-world study value, prompting the Group to continuously upgrade its omnichannel marketing solutions, strengthen evidence-driven approaches, and contribute to high-quality innovative drug development - Precise omnichannel marketing business achieved **significant growth**, with professional capabilities widely recognized by the market, seizing the opportunity of industry recovery[22](index=22&type=chunk) - National policies support the **high-quality development of innovative drugs** and the value of **Real-World Studies (RWS)**; the Group will continuously upgrade its omnichannel marketing solutions and strengthen evidence-driven approaches[22](index=22&type=chunk) [Segment Business Performance](index=5&type=section&id=Segment%20Business%20Performance) [Physician Platform Solutions](index=5&type=section&id=Physician%20Platform%20Solutions) As of June 30, 2025, the platform had approximately **3.3 million** registered physician users, with associate chief physicians and above accounting for about **73.5%** of the total in China; the platform offers rich content across **42** research areas, enhanced by AI for information integration and push capabilities; revenue for the period was approximately **RMB 46.8 million**, a **15%** year-on-year decrease, primarily due to reduced demand for simple language-based clinical research driven by AI technology adoption - As of June 30, 2025, the platform had approximately **3.3 million** registered physician users, with the total number of registered physician users holding associate chief physician titles and above accounting for approximately **73.5%** of all physicians with such titles in China[10](index=10&type=chunk) - Revenue from Physician Platform Solutions was approximately **RMB 46.8 million**, a year-on-year decrease of approximately **15%**, primarily due to reduced demand for simple language-based clinical research driven by the widespread adoption of AI technology[12](index=12&type=chunk) [Precise Omnichannel Marketing Solutions](index=7&type=section&id=Evidence-Driven%20Precise%20Omnichannel%20Marketing%20Solutions) This solution centers on academic-driven digital marketing, emphasizing evidence and professionalism; during the reporting period, business demand grew rapidly, with revenue reaching **RMB 56.1 million**, a **34.1%** year-on-year increase, benefiting from domestic pharmaceutical companies' transition to evidence-driven marketing models; as of June 30, 2025, there were **613** active clients, with a **100%** revenue retention rate for the top 10 clients - Revenue from Precise Omnichannel Marketing Solutions reached **RMB 56.1 million**, a year-on-year increase of approximately **34.1%**, primarily benefiting from the accelerated transition of domestic pharmaceutical companies to evidence-driven marketing models[13](index=13&type=chunk) - As of June 30, 2025, there were **613** active clients, including **525** core pharmaceutical, biotechnology, and medical device enterprise clients, with a **100%** revenue retention rate for the top 10 clients[14](index=14&type=chunk) [Real-World Research Solutions](index=7&type=section&id=Real-World%20Research%20Solutions) The Group provides cost-effective post-market clinical research solutions for pharmaceutical and medical device companies; during the reporting period, revenue was approximately **RMB 16.6 million**, a **22.7%** year-on-year increase, primarily due to actively processing existing orders and AI applications enhancing overall efficiency; **172** projects were executed, with outstanding orders totaling **RMB 195 million** - Revenue from Real-World Research Solutions was approximately **RMB 16.6 million**, a year-on-year increase of **22.7%**, primarily due to actively processing existing orders and AI applications enhancing overall efficiency[16](index=16&type=chunk) - During the reporting period, **172** projects were executed, with outstanding orders decreasing from **RMB 205 million** at the end of 2024 to **RMB 195 million** as of June 30, 2025[16](index=16&type=chunk) [Data and AI Solutions](index=8&type=section&id=Data%20and%20AI%20Solutions) MedSci Healthcare elevates data and AI to a strategic level, applying it internally and actively marketing it to clients; this segment has begun to achieve rapid revenue conversion, with **10** clients and revenue reaching **RMB 5.6 million** during the reporting period, poised to become a new growth engine for the future - Data and AI Solutions have begun to achieve rapid revenue conversion, with **10** clients and revenue reaching **RMB 5.6 million** during the reporting period[18](index=18&type=chunk) - This segment will collaborate with Physician Platform and Precise Omnichannel Marketing Solutions, becoming a new growth engine for the future, continuously exploring AI applications across the entire healthcare value chain[17](index=17&type=chunk) [Financial Statements](index=11&type=section&id=Financial%20Statements) [Interim Condensed Consolidated Statement of Profit or Loss](index=11&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) For the six months ended June 30, 2025, the Group's revenue was **RMB 125,246 thousand**, gross profit was **RMB 77,479 thousand**, profit for the period was **RMB 13,239 thousand**, and both basic and diluted earnings per share were **RMB 2.45 cents** Interim Condensed Consolidated Statement of Profit or Loss (RMB thousands) | Metric | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Revenue | 125,246 | 110,665 | | Cost of Sales | (47,767) | (42,729) | | Gross Profit | 77,479 | 67,936 | | Other Income and Gains | 20,618 | 18,883 | | Selling and Distribution Expenses | (33,764) | (37,850) | | Administrative Expenses | (22,618) | (35,820) | | Research and Development Expenses | (19,689) | (12,022) | | Impairment Loss on Financial and Contract Assets | (7,413) | (519) | | Profit / (Loss) Before Tax | 14,521 | (240) | | Income Tax (Expense) / Credit | (1,282) | 488 | | Profit for the Period | 13,239 | 248 | | Profit Attributable to Owners of the Parent | 13,239 | 248 | | Basic Earnings Per Share | RMB 2.45 cents | RMB 0.05 cents | | Diluted Earnings Per Share | RMB 2.45 cents | RMB 0.05 cents | [Interim Condensed Consolidated Statement of Comprehensive Income](index=12&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) For the six months ended June 30, 2025, the Group's total comprehensive income for the period was **RMB 7,520 thousand**, primarily impacted by exchange differences arising from translating the company's financial statements to the presentation currency Interim Condensed Consolidated Statement of Comprehensive Income (RMB thousands) | Metric | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Profit for the Period | 13,239 | 248 | | Exchange differences arising from translating the financial statements of the Company to presentation currency | (5,473) | 5,751 | | Exchange differences on translation of overseas operations | (246) | 46 | | Other comprehensive (loss) / income for the period, net of tax | (5,719) | 5,797 | | Total comprehensive income for the period | 7,520 | 6,045 | | Attributable to owners of the parent | 7,520 | 6,045 | [Interim Condensed Consolidated Statement of Financial Position](index=13&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, the Group's total assets less current liabilities were **RMB 1,184,437 thousand**, and net assets were **RMB 1,179,739 thousand**; total current assets amounted to **RMB 1,349,519 thousand**, with financial assets at fair value through profit or loss being the largest component Interim Condensed Consolidated Statement of Financial Position (RMB thousands) | Metric | 2025 June 30 (RMB thousands) | 2024 Dec 31 (RMB thousands) | | :--- | :--- | :--- | | Total Non-Current Assets | 34,416 | 28,269 | | Total Current Assets | 1,349,519 | 1,320,987 | | Total Current Liabilities | 199,498 | 179,361 | | Net Current Assets | 1,150,021 | 1,141,626 | | Total Assets Less Current Liabilities | 1,184,437 | 1,169,895 | | Total Non-Current Liabilities | 4,698 | 207 | | Net Assets | 1,179,739 | 1,169,688 | | Total Equity | 1,179,739 | 1,169,688 | [Notes to the Interim Condensed Consolidated Financial Information](index=15&type=section&id=Notes%20to%20the%20Interim%20Condensed%20Consolidated%20Financial%20Information) [Company Information](index=15&type=section&id=Company%20Information) MedSci Healthcare Holdings Limited was incorporated in the Cayman Islands, primarily providing physician platform, precise omnichannel marketing, and real-world research solutions in China; the company's shares have been listed on the Main Board of the Hong Kong Stock Exchange since April 27, 2023 - The Company was incorporated in the **Cayman Islands** on **June 22, 2021**, primarily providing physician platform solutions, precise omnichannel marketing solutions, and real-world research solutions in China[28](index=28&type=chunk) - The Company's shares have been listed on the **Main Board of The Stock Exchange of Hong Kong Limited** since **April 27, 2023**[29](index=29&type=chunk) [Basis of Preparation and Changes in Accounting Policies](index=15&type=section&id=Basis%20of%20Preparation%20and%20Changes%20in%20Accounting%20Policies) The interim condensed consolidated financial information is prepared in accordance with IAS 34 and should be read in conjunction with the 2024 annual consolidated financial statements; revised IFRS were first adopted during this period, but had no significant impact on the financial information - The interim condensed consolidated financial information is prepared in accordance with **International Accounting Standard 34 Interim Financial Reporting** and should be read in conjunction with the Group's annual consolidated financial statements for the year ended December 31, 2024[30](index=30&type=chunk) - The Group first adopted **IAS 21 (Amendment) 'Lack of Exchangeability'**, but it had no impact on the interim condensed consolidated financial information as all currencies traded by the Group are convertible[31](index=31&type=chunk)[32](index=32&type=chunk) [Operating Segment Information](index=16&type=section&id=Operating%20Segment%20Information) The Group primarily operates in Mainland China, providing physician platform, precise omnichannel marketing, and real-world research solutions; no separate operating segment financial information is presented as the chief operating decision-maker reviews the Group's overall financial performance; all revenue and almost all non-current assets are located in Mainland China - The Group is primarily engaged in providing physician platform solutions, precise omnichannel marketing solutions, and real-world research solutions in **Mainland China**[33](index=33&type=chunk) - No further information on operating segments is presented as the directors review the Group's overall financial performance; all of the Group's revenue and almost all non-current assets are generated in or located in **Mainland China**[33](index=33&type=chunk)[34](index=34&type=chunk)[35](index=35&type=chunk) [Revenue Analysis](index=16&type=section&id=Revenue%20Analysis) For the six months ended June 30, 2025, total revenue from contracts with customers was **RMB 125,246 thousand**, entirely from Mainland China, and recognized over time Revenue Analysis (RMB thousands) | Service Type | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Total Services Provided | 125,246 | 110,665 | | Of which: Physician Platform Solutions | 46,828 | 55,246 | | Precise Omnichannel Marketing Solutions | 56,140 | 41,865 | | Real-World Research Solutions | 16,631 | 13,554 | | Data and AI Solutions | 5,647 | N/A | - All revenue is derived from **Mainland China** and recognized over time[39](index=39&type=chunk)[40](index=40&type=chunk) [Details of Profit / (Loss) Before Tax](index=18&type=section&id=Details%20of%20Profit%20%2F%20%28Loss%29%20Before%20Tax) For the six months ended June 30, 2025, profit before tax was **RMB 14,521 thousand**, primarily influenced by increased R&D expenses, higher impairment losses on financial and contract assets, and reduced employee benefit expenses Details of Profit / (Loss) Before Tax (RMB thousands) | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Cost of Services Provided | 25,473 | 21,343 | | Research and Development Expenses | 19,689 | 12,022 | | Net Impairment of Financial Assets (Contract Assets) | 7,383 | 2 | | Bank Interest Income | 7,303 | 10,315 | | Fair Value Gain on Financial Assets at Fair Value Through Profit or Loss | 9,235 | 7,394 | | Total Employee Benefit Expenses | 72,595 | 88,106 | [Income Tax](index=19&type=section&id=Income%20Tax) The Group primarily pays income tax in Mainland China at a statutory rate of **25%**; subsidiary Shanghai MedSci Medical, as a high-tech enterprise, pays corporate income tax at a **15%** rate; for the six months ended June 30, 2025, income tax expense was **RMB 1,282 thousand** - Mainland China subsidiaries pay income tax at a statutory rate of **25%**, while Shanghai MedSci Medical, as a high-tech enterprise, pays at a **15%** rate[43](index=43&type=chunk) Income Tax Expense / (Credit) (RMB thousands) | Metric | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Current — Mainland China expense for the period | 2,242 | — | | Deferred tax | (960) | (488) | | Total tax expense / (credit) for the period | 1,282 | (488) | [Dividends](index=19&type=section&id=Dividends) The Board declared an interim dividend of **1.1 HK cents** per ordinary share on August 29, 2024, totaling approximately **HKD 6,679,000**, to be paid from the share premium account - The Board declared an interim dividend of **1.1 HK cents** per ordinary share (for the six months ended June 30, 2024: nil), totaling approximately **HKD 6,679,000**, to be paid from the Company's share premium account[43](index=43&type=chunk)[89](index=89&type=chunk) [Earnings Per Share Attributable to Owners of the Parent](index=20&type=section&id=Earnings%20Per%20Share%20Attributable%20to%20Owners%20of%20the%20Parent) For the six months ended June 30, 2025, both basic and diluted earnings per share attributable to owners of the parent were **RMB 2.45 cents**, calculated based on a weighted average of **540,682,205** ordinary shares outstanding Earnings Per Share Calculation (RMB thousands/share) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Profit Attributable to Owners of the Parent (RMB thousands) | 13,239 | 248 | | Weighted Average Number of Ordinary Shares in Issue | 540,682,205 | 540,330,093 | | Basic Earnings Per Share | RMB 2.45 cents | RMB 0.05 cents | | Diluted Earnings Per Share | RMB 2.45 cents | RMB 0.05 cents | - No adjustment was made to the basic earnings per share amount for dilution, as the share award scheme had an anti-dilutive effect on the reported basic earnings per share amount[44](index=44&type=chunk) [Property, Plant and Equipment](index=21&type=section&id=Property%2C%20Plant%20and%20Equipment) As of June 30, 2025, the net book value of property, plant and equipment was **RMB 15,070 thousand**, with depreciation for the period amounting to **RMB 593 thousand** Net Book Value of Property, Plant and Equipment (RMB thousands) | Item | Amount (RMB thousands) | | :--- | :--- | | As at January 1, 2025 (audited) | 15,663 | | Depreciation | (593) | | As at June 30, 2025 (unaudited) | 15,070 | [Trade Receivables](index=21&type=section&id=Trade%20Receivables) As of June 30, 2025, total trade receivables amounted to **RMB 31,217 thousand**, with the vast majority due within one year Ageing Analysis of Trade Receivables (RMB thousands) | Ageing | 2025 June 30 (RMB thousands) | 2024 Dec 31 (RMB thousands) | | :--- | :--- | :--- | | Within 1 year | 29,271 | 30,987 | | 1 to 2 years | 1,903 | 1,992 | | 2 to 3 years | 43 | 47 | | Total | 31,217 | 33,026 | [Trade Payables](index=21&type=section&id=Trade%20Payables) As of June 30, 2025, total trade payables amounted to **RMB 563 thousand**, all due within three months Ageing Analysis of Trade Payables (RMB thousands) | Ageing | 2025 June 30 (RMB thousands) | 2024 Dec 31 (RMB thousands) | | :--- | :--- | :--- | | Within 3 months | 563 | 2,031 | [Share Capital](index=22&type=section&id=Issued%20Capital) As of June 30, 2025, the Company's issued share capital consisted of **607,170,950** ordinary shares with a par value of **USD 0.0001** each, totaling **RMB 420 thousand** Issued Share Capital (RMB thousands) | Item | 2025 June 30 Number of Shares | 2025 June 30 Amount (RMB thousands) | | :--- | :--- | :--- | | Issued ordinary shares (par value USD 0.0001 each) | 607,170,950 | 420 | [Approval of Interim Financial Information](index=22&type=section&id=Approval%20of%20Interim%20Financial%20Information) The interim condensed consolidated financial information was approved and authorized for issue by the Board of Directors on August 29, 2025 - The interim condensed consolidated financial information was approved and authorized for issue by the Board of Directors on **August 29, 2025**[50](index=50&type=chunk) [Management Discussion and Analysis](index=23&type=section&id=Management%20Discussion%20and%20Analysis) [Revenue Analysis](index=23&type=section&id=Revenue%20Analysis) Total revenue for H1 2025 increased by **13.2%** year-on-year to **RMB 125.2 million**, primarily driven by the recovery of the pharmaceutical industry and the transition to evidence-driven marketing models - The Group's total revenue increased by **13.2%** from approximately **RMB 110.7 million** for the six months ended June 30, 2024, to approximately **RMB 125.2 million** during the reporting period[51](index=51&type=chunk) - Revenue growth was primarily due to the recovery of the pharmaceutical industry and the accelerated transition of domestic pharmaceutical companies to evidence-driven marketing models, driving increased demand for precise omnichannel marketing solutions[51](index=51&type=chunk) [Revenue from Precise Omnichannel Marketing Solutions](index=23&type=section&id=(i)%20Precise%20Omnichannel%20Marketing%20Solutions) Revenue from this solution increased by **34.1%** year-on-year to **RMB 56.1 million**, primarily benefiting from the pharmaceutical industry's recovery and domestic pharmaceutical companies' accelerated transition to evidence-driven marketing models - Revenue from Precise Omnichannel Marketing Solutions increased by approximately **34.1%** from approximately **RMB 41.9 million** to approximately **RMB 56.1 million**[52](index=52&type=chunk) - The increase was primarily due to the recovery of the pharmaceutical industry and the accelerated transition of domestic pharmaceutical companies to evidence-driven marketing models[52](index=52&type=chunk) [Revenue from Physician Platform Solutions](index=23&type=section&id=(ii)%20Physician%20Platform%20Solutions) Revenue from Physician Platform Solutions decreased by **15%** year-on-year to **RMB 46.8 million**, primarily due to reduced demand for simple language-based clinical research driven by AI technology adoption - Revenue from Physician Platform Solutions decreased by approximately **15%** from approximately **RMB 55.2 million** to approximately **RMB 46.8 million**[53](index=53&type=chunk) - The decrease was primarily driven by the widespread adoption of AI technology, which reduced demand for simple language-based clinical research[53](index=53&type=chunk) [Revenue from RWS Solutions](index=24&type=section&id=(iii)%20RWS%20Solutions) Revenue from RWS Solutions increased by **22.7%** year-on-year to **RMB 16.6 million**, primarily benefiting from actively processing existing orders and AI applications enhancing research efficiency - Revenue from RWS Solutions increased by approximately **22.7%** from approximately **RMB 13.6 million** to approximately **RMB 16.6 million**[54](index=54&type=chunk) - The increase was primarily due to the Group actively processing existing orders and AI applications enhancing the overall efficiency of real-world research[54](index=54&type=chunk) [Revenue from Data and AI Solutions](index=24&type=section&id=(iv)%20Data%20and%20AI%20Solutions) Revenue from Data and AI Solutions was **RMB 5.6 million**, primarily due to rapidly increasing industry demand for related products and services - Revenue from Data and AI Solutions was **RMB 5.6 million**, primarily due to rapidly increasing industry demand for related products and services[55](index=55&type=chunk) [Costs and Gross Profit](index=24&type=section&id=Costs%20and%20Gross%20Profit) Cost of sales increased by **11.8%** year-on-year to **RMB 47.8 million**, gross profit grew by **14.1%** to **RMB 77.5 million**, and gross margin slightly increased to **61.9%** - Cost of sales primarily includes employee benefit expenses, content development costs, conference fees, and office expenses[56](index=56&type=chunk) [Cost of Sales](index=24&type=section&id=Cost%20of%20Sales) Cost of sales increased by **11.8%** year-on-year to **RMB 47.8 million**, primarily rising proportionally with the expansion of revenue scale - Cost of sales increased by approximately **11.8%** from approximately **RMB 42.8 million** for the six months ended June 30, 2024, to approximately **RMB 47.8 million** for the same period in 2025, primarily due to a proportional increase in costs with the expansion of revenue scale[56](index=56&type=chunk) [Gross Profit and Gross Margin](index=24&type=section&id=Gross%20Profit%20and%20Gross%20Margin) Gross profit increased by **14.1%** year-on-year to **RMB 77.5 million**, with gross margin slightly rising from **61.4%** in the same period of 2024 to **61.9%** in 2025 - Gross profit increased by approximately **14.1%** from approximately **RMB 67.9 million** for the six months ended June 30, 2024, to approximately **RMB 77.5 million** for the same period in 2025[57](index=57&type=chunk) - For the six months ended June 30, 2025, the gross margin was approximately **61.9%**, a slight increase from **61.4%** in the same period of 2024[57](index=57&type=chunk) [Other Income and Expenses](index=25&type=section&id=Other%20Income%20and%20Expenses) Other income and gains were primarily influenced by fair value changes and government subsidies; selling and distribution expenses and administrative expenses decreased, while R&D expenses and impairment losses on financial and contract assets increased - Other income and gains were approximately **RMB 20.6 million**, with the increase primarily due to fair value changes and government subsidies[58](index=58&type=chunk) [Other Income and Gains](index=25&type=section&id=Other%20Income%20and%20Gains) Other income and gains were approximately **RMB 20.6 million**, an increase from **RMB 18.9 million** in the same period of 2024, primarily due to fair value changes and government subsidies - For the six months ended June 30, 2025, other income and gains were approximately **RMB 20.6 million**, compared to approximately **RMB 18.9 million** in the same period of 2024, with the increase primarily due to fair value changes and government subsidies[58](index=58&type=chunk) [Selling and Distribution Expenses](index=25&type=section&id=Selling%20and%20Distribution%20Expenses) Selling and distribution expenses decreased by **10.8%** year-on-year to **RMB 33.8 million**, primarily due to improved sales personnel effectiveness and enhanced company refined management capabilities - Selling and distribution expenses decreased by approximately **10.8%** from approximately **RMB 37.9 million** for the six months ended June 30, 2024, to approximately **RMB 33.8 million** for the same period in 2025, primarily due to improved sales personnel effectiveness and enhanced company refined management capabilities[59](index=59&type=chunk) [Administrative Expenses](index=25&type=section&id=Administrative%20Expenses) Administrative expenses decreased by **36.9%** year-on-year to **RMB 22.6 million**, primarily because no new share incentive schemes were introduced during the reporting period, and share-based payment expenses recognized in the prior year period did not recur - Administrative expenses decreased by approximately **36.9%** from approximately **RMB 35.8 million** for the six months ended June 30, 2024, to approximately **RMB 22.6 million** for the same period in 2025, primarily because no new share incentive schemes were introduced during the reporting period, and share-based payment expenses recognized in the prior year period did not recur[60](index=60&type=chunk) [Research and Development Expenses](index=26&type=section&id=Research%20and%20Development%20Expenses) R&D expenses increased by **63.8%** year-on-year to **RMB 19.7 million**, primarily due to the Group's increased resource allocation to the AI sector - R&D expenses increased by approximately **63.8%** from approximately **RMB 12.0 million** for the six months ended June 30, 2024, to approximately **RMB 19.7 million** for the same period in 2025, primarily due to the Group's increased resource allocation to the AI sector[61](index=61&type=chunk) [Impairment Loss on Financial and Contract Assets](index=26&type=section&id=Impairment%20Loss%20on%20Financial%20and%20Contract%20Assets) Impairment loss on financial and contract assets increased from **RMB 0.5 million** to **RMB 7.4 million**, primarily arising from the impairment of trade receivables, contract assets, and other assets - For the six months ended June 30, 2024 and 2025, impairment losses on financial and contract assets were approximately **RMB 0.5 million** and **RMB 7.4 million**, respectively, primarily arising from the impairment of trade receivables, contract assets, and other assets[62](index=62&type=chunk) [Finance Costs](index=26&type=section&id=Finance%20Costs) Finance costs primarily represent interest on lease liabilities, amounting to approximately **RMB 92,000** during the reporting period - Finance costs primarily refer to interest on lease liabilities; for the six months ended 2025, finance costs of approximately **RMB 92,000** were recorded[63](index=63&type=chunk) [Profit Before Tax and for the Period](index=26&type=section&id=Profit%20Before%20Tax%20and%20for%20the%20Period) For the six months ended June 30, 2025, the Group achieved a profit before tax of **RMB 14.5 million** and a profit for the period of **RMB 13.2 million**, with net profit margin increasing from **0.2%** to **10.6%** - A profit before tax of approximately **RMB 14.5 million** was generated for the six months ended June 30, 2025, compared to a profit before tax of approximately **RMB (0.2) million** for the six months ended June 30, 2024[64](index=64&type=chunk) [Profit / (Loss) Before Tax](index=26&type=section&id=Profit%20%2F%20%28Loss%29%20Before%20Tax) For the six months ended June 30, 2025, the Group generated a profit before tax of approximately **RMB 14.5 million**, compared to a loss before tax of approximately **RMB 0.2 million** in the same period of 2024 - A profit before tax of approximately **RMB 14.5 million** was generated for the six months ended June 30, 2025, compared to a profit before tax of approximately **RMB (0.2) million** for the six months ended June 30, 2024[64](index=64&type=chunk) [Income Tax Credit / (Expense)](index=26&type=section&id=Income%20Tax%20Credit%20%2F%20%28Expense%29) For the six months ended June 30, 2025, the Group incurred an income tax expense of **RMB 1.3 million**, compared to an income tax credit of approximately **RMB 0.5 million** in the same period of 2024, primarily due to increased revenue - An income tax expense of **RMB 1.3 million** was incurred for the six months ended June 30, 2025, compared to an income tax credit of approximately **RMB 0.5 million** in the same period of 2024, primarily due to increased revenue[65](index=65&type=chunk) [Profit for the Period and Profit Attributable to Owners of the Parent](index=27&type=section&id=Profit%20for%20the%20Period%20and%20Profit%20Attributable%20to%20Owners%20of%20the%20Parent) For the six months ended June 30, 2025, the Group's profit for the period was approximately **RMB 13.2 million**, with net profit margin increasing from **0.2%** in the same period of 2024 to **10.6%** - A profit for the period of approximately **RMB 13.2 million** was generated for the six months ended 2025, compared to approximately **RMB 0.2 million** for the same period in 2024[66](index=66&type=chunk) - The net profit margin (calculated based on profit for the period) increased from approximately **0.2%** for the six months ended June 30, 2024, to approximately **10.6%** for the same period in 2025[66](index=66&type=chunk) [Liquidity and Capital Resources](index=27&type=section&id=Liquidity%20and%20Capital%20Resources) The Group primarily funds its capital needs through cash generated from operations and net proceeds from the global offering; as of June 30, 2025, cash and cash equivalents were approximately **RMB 315.6 million**, with no bank borrowings and a zero gearing ratio - The Group primarily funds its future capital needs through cash generated from operations and net proceeds from the global offering[67](index=67&type=chunk) [Cash and Cash Equivalents](index=27&type=section&id=Cash%20and%20Cash%20Equivalents) As of June 30, 2025, cash and cash equivalents were approximately **RMB 315.6 million**, a decrease from approximately **RMB 366.9 million** as of December 31, 2024; the Group faces no significant foreign currency exchange rate fluctuation risk regarding cash generated from operating activities, but net proceeds from the global offering are denominated in HKD, exposing the Company to RMB and HKD exchange rate fluctuation risk - As of June 30, 2025, the Group had cash and cash equivalents of approximately **RMB 315.6 million**, compared to approximately **RMB 366.9 million** as of December 31, 2024[68](index=68&type=chunk) - The net proceeds from the global offering received by the Company are denominated in **HKD**, exposing the Company to the risk of exchange rate fluctuations between **RMB** and **HKD**[68](index=68&type=chunk) [Bank Facilities](index=27&type=section&id=Bank%20Facilities) For the six months ended June 30, 2025, the Group had no bank borrowings or other interest-bearing borrowings, and no outstanding bank and other borrowings or other debts apart from lease liabilities - For the six months ended June 30, 2025, the Group had no bank borrowings or other interest-bearing borrowings, and no outstanding bank and other borrowings or other debts apart from lease liabilities totaling approximately **RMB 8.3 million** under relevant lease terms[69](index=69&type=chunk) [Gearing Ratio](index=28&type=section&id=Gearing%20Ratio) As there was no debt as of June 30, 2025, the gearing ratio was zero - As there was no debt as of June 30, 2025, the gearing ratio (calculated as borrowings divided by total equity) was **zero**[70](index=70&type=chunk) [Pledge of Assets](index=28&type=section&id=Pledge%20of%20Assets) As of June 30, 2025, the Group had not pledged any assets - As of June 30, 2025, the Group had not pledged any assets[71](index=71&type=chunk) [Capital Expenditure and Commitments](index=28&type=section&id=Capital%20Expenditure%20and%20Commitments) As of June 30, 2025, the Group had no significant capital expenditure or capital commitments - As of June 30, 2025, the Group had no significant capital expenditure[72](index=72&type=chunk) - As of June 30, 2025, the Group had no significant capital commitments[73](index=73&type=chunk) [Contingent Liabilities](index=28&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the Group had no significant contingent liabilities - As of June 30, 2025, the Group had no significant contingent liabilities[74](index=74&type=chunk) [Employees, Staff Costs and Remuneration Policy](index=28&type=section&id=Employees%2C%20Staff%20Costs%20and%20Remuneration%20Policy) As of August 29, 2025, the Group had **451** full-time employees, with total staff costs of approximately **RMB 70.1 million**; the Group provides remuneration, bonuses, and benefits, along with employee training - As of **August 29, 2025**, the Group had **451** full-time employees, all located in China[75](index=75&type=chunk) - For the six months ended June 30, 2025, the Group incurred total staff costs of approximately **RMB 70.1 million**, compared to approximately **RMB 88.1 million** in the same period of 2024[75](index=75&type=chunk) - The Group provides employees with remuneration and bonuses, as well as employee benefits, including employee retirement benefit schemes, medical and work injury insurance schemes, and housing provident fund schemes[75](index=75&type=chunk) [Other Information](index=29&type=section&id=Other%20Information) [Corporate Governance](index=29&type=section&id=Corporate%20Governance) The Company is committed to maintaining and enhancing its corporate governance standards and has complied with all applicable code provisions of the Corporate Governance Code set out in Appendix C1 of the Listing Rules - The Company has adopted the relevant provisions of the **Corporate Governance Code** set out in **Appendix C1 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited** as the basis for its corporate governance practices[76](index=76&type=chunk) - The Board believes that for the six months ended June 30, 2025, the Company has complied with all applicable code provisions of the Corporate Governance Code then in effect[76](index=76&type=chunk) [Compliance with Corporate Governance Code](index=29&type=section&id=Compliance%20with%20Corporate%20Governance%20Code) The Company has adopted and complied with the relevant provisions of the Corporate Governance Code set out in Appendix C1 of the Listing Rules and will continue to review and monitor its corporate governance practices - The Company has adopted the relevant provisions of the **Corporate Governance Code** set out in **Appendix C1 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited** as the basis for its corporate governance practices[76](index=76&type=chunk) - The Board believes that for the six months ended June 30, 2025, the Company has complied with all applicable code provisions of the Corporate Governance Code then in effect[76](index=76&type=chunk) [Compliance with Model Code for Securities Transactions](index=29&type=section&id=Compliance%20with%20Model%20Code%20for%20Securities%20Transactions) The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 of the Listing Rules; directors have confirmed compliance with the code during the reporting period, and no employee breaches were identified - The Company has adopted the **Model Code for Securities Transactions by Directors of Listed Issuers** set out in **Appendix C3 of the Listing Rules**, and all directors have confirmed their compliance with the Model Code for the six months ended June 30, 2025[77](index=77&type=chunk) [Transactions in Listed Securities](index=29&type=section&id=Transactions%20in%20Listed%20Securities) For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities, nor held any treasury shares - For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[78](index=78&type=chunk) - As of June 30, 2025, neither the Company nor any of its subsidiaries held any treasury shares[79](index=79&type=chunk) [Purchase, Sale or Redemption of Listed Securities](index=29&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Listed%20Securities) For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities - For the six months ended June 30, 2025, neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's listed securities[78](index=78&type=chunk) [Use of Proceeds](index=30&type=section&id=Use%20of%20Proceeds) The Company's net proceeds from the global offering were approximately **HKD 526.8 million**; as of June 30, 2025, **HKD 19.7 million** had been utilized for technology development, with an unutilized amount of **HKD 425.6 million**; the expected full utilization period for business expansion and technology development has been updated to December 2026 - The net proceeds received by the Company from the global offering were approximately **HKD 526.8 million**[80](index=80&type=chunk) Use of Proceeds from Global Offering (HKD millions) | Purpose | Net Proceeds from Global Offering (HKD millions) | Amount Utilized (January 1, 2025 to June 30, 2025) (HKD millions) | Unutilized Amount (as of June 30, 2025) (HKD millions) | | :--- | :--- | :--- | :--- | | Business Expansion | 237.1 | — | 232.1 | | Further Technology Development | 184.4 | 19.7 | 119.8 | | Potential Investments and Acquisitions | 79.0 | — | 73.7 | | Working Capital and General Corporate Purposes | 26.3 | — | — | | Total | 526.8 | 19.7 | 425.6 | - The expected full utilization period for net proceeds for 'Business Expansion' and 'Further Technology Development' has been updated to **December 2026**[80](index=80&type=chunk) [Material Investments, Acquisitions and Disposals](index=30&type=section&id=Material%20Investments%2C%20Acquisitions%20and%20Disposals) Except for investments in subsidiaries, the Group held no material investments as of June 30, 2025, and there were no other material acquisitions or disposals during the reporting period - Except for investments in subsidiaries, the Group held no material investments as of **June 30, 2025**[81](index=81&type=chunk) - During the reporting period, the Group had no other material acquisitions or disposals of subsidiaries, associates, and joint ventures[81](index=81&type=chunk) [Changes in Directors' Information](index=31&type=section&id=Changes%20in%20Directors'%20Information) During the reporting period, Dr. Zhang Fabao ceased to be Chairman of the Nomination Committee and was appointed as a member of the Remuneration Committee; Dr. Li Xinmei ceased to be a member of the Remuneration Committee and was appointed as a member of the Nomination Committee; Mr. Liu Yaokun was appointed as Chairman of the Nomination Committee - Dr. Zhang Fabao ceased to be the Chairman of the Board's Nomination Committee and was appointed as a member of the Board's Remuneration Committee, effective **June 30, 2025**[87](index=87&type=chunk) - Dr. Li Xinmei ceased to be a member of the Remuneration Committee and was appointed as a member of the Nomination Committee, effective **June 30, 2025**[87](index=87&type=chunk) - Mr. Liu Yaokun was appointed as the Chairman of the Nomination Committee, effective **June 30, 2025**[87](index=87&type=chunk) [Significant Events After Reporting Period](index=31&type=section&id=Significant%20Events%20After%20Reporting%20Period) Except as disclosed in this announcement, no other significant events occurred from June 30, 2025, up to the date of this announcement - Except as disclosed in this announcement, no other significant events occurred from **June 30, 2025**, up to the date of this announcement[85](index=85&type=chunk) [Review by Audit Committee](index=31&type=section&id=Review%20by%20Audit%20Committee) The Board's Audit Committee has reviewed the Group's unaudited consolidated interim results for the six months ended June 30, 2025, deeming them compliant with applicable accounting standards, laws, and regulations - The Audit Committee has reviewed the Group's unaudited consolidated interim results for the six months ended **June 30, 2025**, with the Company's management[88](index=88&type=chunk) - The Audit Committee believes that the Group's unaudited consolidated interim results for the six months ended **June 30, 2025**, comply with applicable accounting standards, laws, and regulations[88](index=88&type=chunk) [Declaration and Payment of Dividends](index=32&type=section&id=Declaration%20and%20Payment%20of%20Dividends) The Board resolved to pay an interim dividend of **1.1 HK cents** per share, funded by the share premium account, expected to be paid on or about October 30, 2025, to shareholders registered on October 10, 2025 - The Board resolved to pay an interim dividend of **1.1 HK cents** per share for the six months ended June 30, 2025 (nil for the same period in 2024), which will be paid from the Company's share premium account[89](index=89&type=chunk) - The interim dividend is expected to be paid on or about **October 30, 2025**, to shareholders whose names appear on the Company's register of members on **October 10, 2025**[89](index=89&type=chunk) [Closure of Register of Members](index=32&type=section&id=Closure%20of%20Register%20of%20Members) To determine shareholders entitled to the interim dividend, the Company will suspend its register of members from October 6, 2025, to October 10, 2025 - The Company's register of members will be closed from **Monday, October 6, 2025**, to **Friday, October 10, 2025** (both dates inclusive), during which no transfer of shares will be registered[91](index=91&type=chunk) - The record date for determining shareholders entitled to the interim dividend is **Friday, October 10, 2025**[91](index=91&type=chunk) [Publication of Interim Results Announcement and Interim Report](index=33&type=section&id=Publication%20of%20Interim%20Results%20Announcement%20and%20Interim%20Report) This announcement has been published on the HKEX website and the Company's website, and the interim report containing all required information will be published in due course - This announcement is published on the **HKEX website (www.hkexnews.hk)** and the **Company's website (https://ir.medsci.cn/zh_cn)**[92](index=92&type=chunk) - The Company's interim report for the six months ended **June 30, 2025**, containing all information required by the Listing Rules, will be published in due course on the respective websites of the HKEX and the Company[92](index=92&type=chunk)

Core Viewpoint - Meiz Health (02415.HK) anticipates a significant increase in shareholder profit for the six months ending June 30, 2025, projecting at least RMB 10 million, compared to a mere RMB 200,000 for the same period in 2024 [1] Group 1: Profit Forecast - The company expects a substantial rise in profit primarily due to the recovery in the pharmaceutical industry [1] - The shift towards evidence-driven marketing models among domestic pharmaceutical companies is driving demand for precise omnichannel marketing solutions [1] - The application of artificial intelligence is enhancing production efficiency across various business segments [1] - The active implementation of environmental, social, and governance (ESG) principles is leading to more effective control of operational costs [1]